Figures & data
Table I. Targets for CAR-modified T cells.
Table II. Different characteristics of the four generations of CAR T cells.
Table III. Clinical trials with different types of CAR-modified T cells.
Brentjens RJ, Rivière I, Park JH, Davila ML, Wang X, Stefanski J, et al. 2011. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood. 118:4817–4828. Brentjens RJ, Santos E, Nikhamin Y, Yeh R, Matsushita M, La Perle K, et al. 2007. Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin Cancer Res. 13:5426–5435. Hollyman D, Stefanski J, Przybylowski M, Bartido S, Borquez-Ojeda O, Taylor C, et al. 2009. Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy. J Immunother. 32:169. Jena B, Maiti S, Huls H, Singh H, Lee DA, Champlin RE, Cooper LJ. 2013. Chimeric antigen receptor (CAR)-specific monoclonal antibody to detect CD19-specific T cells in clinical trials. PloS one. 8:e57838. Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO, Stetler-Stevenson M, et al. 2014. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 33:540–549. Kowolik CM, Topp MS, Gonzalez S, Pfeiffer T, Olivares S, Gonzalez N, et al. 2006. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res. 66:10995–11004. Lee JC, Hayman E, Pegram HJ, Santos E, Heller G, Sadelain M, Brentjens R. 2011. In vivo inhibition of human CD19-targeted effector T cells by natural T regulatory cells in a xenotransplant murine model of B cell malignancy. Cancer Res. 71:2871–2881. Savoldo B, Ramos CA, Liu E, Mims MP, Keating MJ, Carrum G, et al. 2011. CD28 costimulation improves expansion and persistence of chimeric antigen receptor–modified T cells in lymphoma patients. J Clin Invest. 121:1822. Till BG, Jensen MC, Wang J, Chen EY, Wood BL, Greisman HA, et al. 2008. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood. 112:2261–2271. Till BG, Jensen MC, Wang J, Qian X, Gopal AK, Maloney DG, et al. 2012. CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4–1BB domains: pilot clinical trial results. Blood. 119:3940–3950. Wang J, Press OW, Lindgren CG, Greenberg P, Riddell S, Qian X, et al. 2004. Cellular immunotherapy for follicular lymphoma using genetically modified CD20-specific CD8 + cytotoxic T lymphocytes. Mol Ther. 9:577–586. Vera J, Savoldo B, Vigouroux S, Biagi E, Pule M, Rossig C, et al. 2006. T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. Blood. 108:3890–3897. Di Stasi A, De Angelis B, Rooney CM, Zhang L, Mahendravada A, Foster AE, et al. 2009. T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood. 113:6392–6402. Hudecek M, Schmitt TM, Baskar S, Lupo-Stanghellini MT, Nishida T, Yamamoto TN, et al. 2010. The B-cell tumor–associated antigen ROR1 can be targeted with T cells modified to express a ROR1- specific chimeric antigen receptor. Blood. 116:4532–4541. Kailayangiri S, Altvater B, Meltzer J, Pscherer S, Luecke A, Dierkes C, et al. 2012. The ganglioside antigen GD2 is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting. Br J Cancer. 106:1123–1133. Louis CU, Savoldo B, Dotti G, Pule M, Yvon E, Myers GD, et al. 2011. Antitumor activity and long-term fate of chimeric antigen receptor– positive T cells in patients with neuroblastoma. Blood. 118:6050–6056. Pule MA, Savoldo B, Myers GD, Rossig C, Russell HV, Dotti G, et al. 2008. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med. 14:1264–1270. Park JR, Digiusto DL, Slovak M, Wright C, Naranjo A, Wagner J, et al. 2007. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol Ther. 15:825–833. Hwu P, Shafer G, Treisman J, Schindler D, Gross G, Cowherd R, et al. 1993. Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain. J Exp Med. 178:361–366. Niederman TM, Ghogawala Z, Carter BS, Tompkins HS, Russell MM, Mulligan RC. 2002. Antitumor activity of cytotoxic T lymphocytes engineered to target vascular endothelial growth factor receptors. Proc Natl Acad Sci USA. 99:7009–7014. Haynes NM, Trapani JA, Teng MW, Jackson JT, Cerruti L, Jane SM, et al. 2002. Rejection of syngeneic colon carcinoma by CTLs expressing single-chain antibody receptors codelivering CD28 costimulation. J Immunol. 169:5780–5786. Hombach A, Schneider C, Sent D, Koch D, Willemsen RA, Diehl V, et al. 2000. An entirely humanized CD3 zeta-chain signaling receptor that directs peripheral blood t cells to specific lysis of carcinoembryonic antigen-positive tumor cells. Int J Cancer. 88:115–120. Katz SC, Burga RA, Mccormack E, Wang LJ, Mooring JW, Point G, et al. 2015. Phase I hepatic immunotherapy for metastases study of intra-arterial chimeric antigen receptor modified T cell therapy for CEA+ liver metastases. Clin Cancer Res. 1421.2014. Pinthus JH, Waks T, Kaufman-Francis K, Schindler DG, Harmelin A, Kanety H, et al 2003. Immuno-gene therapy of established prostate tumors using chimeric receptor-redirected human lymphocytes. Cancer Res. 63:2470–2476. Teng MW, Kershaw MH, Moeller M, Smyth MJ, Darcy PK. 2004. Immunotherapy of cancer using systemically delivered gene-modified human T lymphocytes. Hum Gene Ther. 15:699–708. Muniappan A, Banapour B, Lebkowski J, Talib S. 2000. Ligand- mediated cytolysis of tumor cells: use of heregulin-ζ chimeras to redirect cytotoxic T lymphocytes. Cancer Gene Ther. 7:128–134. Lamers CH, Sleijfer S, Vulto AG, Kruit WH, Kliffen M, Debets R, et al. 2006. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol. 24:e20–e22. Lamers CH, Willemsen R, Van Elzakker P, Van Steenbergen-Langeveld S, Broertjes M, Oosterwijk-Wakka J, et al. 2011. Immune responses to transgene and retroviral vector in patients treated with ex vivo–engineered T cells. Blood. 117:72–82. Mezzanzanica D, Canevari S, Mazzoni A, Figini M, Colnaghi MI, Waks T, et al. 1997. Transfer of chimeric receptor gene made of variable regions of tumor-specific antibody confers anticarbohydrate specificity on T cells. Cancer Gene Ther. 5:401–407. Westwood JA, Smyth MJ, Teng MW, Moeller M, Trapani JA, Scott AM, et al. 2005. Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice. Proc Natl Acad Sci USA. 102:19051–19056. Gong MC, Latouche J-B, Krause A, Heston WD, Bander NH, Sadelain M. 1999. Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen. Neoplasia. 1:123. Maher J, Brentjens RJ, Gunset G, Rivière I, Sadelain M. 2002. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ/CD28 receptor. Nat Biotechnol. 20:70–75. Rosenberg SA, Dudley ME. 2009. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol. 21:233–240. Morgan RA, Chinnasamy N, Abate-Daga D, Gros A, Robbins PF, Zheng Z, et al. 2013. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother. 36:133–151. Spear P, Barber A, Rynda-Apple A, Sentman CL. 2012. Chimeric antigen receptor T cells shape myeloid cell function within the tumor microenvironment through IFN-γ and GM-CSF. J Immunol. 188:6389–6398. Carpenito C, Milone MC, Hassan R, Simonet JC, Lakhal M, Suhoski MM, et al. 2009. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci USA. 106:3360–3365. Kahlon KS, Brown C, Cooper LJ, Raubitschek A, Forman SJ, Jensen MC. 2004. Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. Cancer Res. 64:9160–9166. Chekmasova AA, Rao TD, Nikhamin Y, Park KJ, Levine DA, Spriggs DR, Brentjens RJ. 2010. Successful eradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen. Clin Cancer Res. 16:3594–3606. Koneru M, Purdon TJ, Spriggs D, Koneru S, Brentjens RJ. 2015. IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo. Oncoimmunology. 4:e994446. Pameijer C, Navanjo A, Meechoovet B, Wagner J, Aguilar B, Wright C, et al. 2007. Conversion of a tumor-binding peptide identified by phage display to a functional chimeric T cell antigen receptor. Cancer Gene Ther. 14:91–97. Sharifzadeh Z, Rahbarizadeh F, Shokrgozar MA, Ahmadvand D, Mahboudi F, Jamnani FR, Moghimi SM. 2013. Genetically engineered T cells bearing chimeric nanoconstructed receptors harboring TAG-72-specific camelid single domain antibodies as targeting agents. Cancer Lett. 334:237–244.